文章目录

c-Rel是一种用于癌症免疫治疗的髓细胞检查点

原文发布日期：2020-05-18

英文摘要：

摘要翻译：

原文链接：

文章：

c-Rel是一种用于癌症免疫治疗的髓细胞检查点

c-Rel is a myeloid checkpoint for cancer immunotherapy

原文发布日期：2020-05-18

英文摘要：

Immunotherapy that targets lymphoid cell checkpoints holds great promise for curing cancer. However, many cancer patients do not respond to this form of therapy. In addition to lymphoid cells, myeloid cells play essential roles in controlling immunity to cancer. Whether myeloid checkpoints exist that can be targeted to treat cancer is not well established. Here we show that c-Rel, a member of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) family, specified the generation of myeloid-derived suppressor cells by selectively turning on protumoral genes while switching off antitumoral genes through a c-Rel enhanceosome. c-Rel deficiency in myeloid cells markedly inhibited cancer growth in mice and pharmaceutical inhibition of c-Rel had the same effect. Combination therapy that blocked both c-Rel and the lymphoid checkpoint protein programmed cell death protein 1 was more effective in treating cancer than blocking either alone. Thus, c-Rel is a myeloid checkpoint that can be targeted for treating cancer.

摘要翻译：

针对淋巴样细胞检查点的免疫疗法对治疗癌症大有希望。然而，许多癌症患者对这种治疗没有反应。除淋巴样细胞外，髓样细胞在控制对癌症的免疫中起着重要作用。骨髓检查点是否存在可以靶向治疗癌症还没有很好的确定。本研究表明，活化B细胞（NF-κB）家族的核因子kappa轻链增强子c-Rel通过选择性地打开原肿瘤基因，同时通过c-Rel增强体关闭抗肿瘤基因，从而指定髓源性抑制细胞的产生。骨髓细胞c-Rel缺乏明显抑制小鼠肿瘤生长，药物抑制c-Rel具有相同的效果。阻断c-Rel和淋巴细胞检查点蛋白程序性细胞死亡蛋白1的联合治疗在治疗癌症方面比单独阻断任何一种更有效。因此，c-Rel是一种可以靶向治疗癌症的髓细胞检查点。